EA202191075A1 - Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний - Google Patents
Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеванийInfo
- Publication number
- EA202191075A1 EA202191075A1 EA202191075A EA202191075A EA202191075A1 EA 202191075 A1 EA202191075 A1 EA 202191075A1 EA 202191075 A EA202191075 A EA 202191075A EA 202191075 A EA202191075 A EA 202191075A EA 202191075 A1 EA202191075 A1 EA 202191075A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- difluoromethoxy
- trifluoromethyl
- methoxy
- chlorine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к новым соединениям и к способу лечения заболевания сетчатки, приводящего к потере фоторецепторов или дегенерации наружных слоев сетчатки, включающему введение соединения формулы (I)или его фармацевтически приемлемой соли, рацемической смеси, соответствующего энантиомера или, если применимо, соответствующего диастереомера, где A выбран из группы, состоящей 5-оксазолильного, пиридин-4-ильного, триазолильного, оксадиазолильного, имидазолильного и 2-метилоксазол-5-ильного остатка, R1 и R12 независимо выбраны из группы, состоящей из водорода, фтора, хлора, метокси, трифторметила, метила и дифторметокси, В выбран из группы, состоящей из остатка формулы (II), (III), (IV), (V), (VI), (VII), (VIII) и (IX)где "*" указывает место присоединения к остальной части молекулы, и R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V, R2VI, R3VI, R4VI, R5VI, R2VII, R3VII, R4VII и R5VII независимо выбраны из группы, состоящей из водорода, линейного или разветвленного алкила, содержащего от 1 до 3 атомов углерода, фтора, хлора, брома, метокси, этокси, пропокси, 2,2,2-трифторметила и дифторметокси.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/235,429 US10807973B2 (en) | 2018-12-28 | 2018-12-28 | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| PCT/US2019/068768 WO2020140050A1 (en) | 2018-12-28 | 2019-12-27 | N-(4-(oxazol-5-yl)phenyl)chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191075A1 true EA202191075A1 (ru) | 2021-10-06 |
Family
ID=69191293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191075A EA202191075A1 (ru) | 2018-12-28 | 2019-12-27 | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10807973B2 (ru) |
| EP (1) | EP3902798B1 (ru) |
| JP (1) | JP7492964B2 (ru) |
| KR (1) | KR20210110652A (ru) |
| CN (1) | CN113227086A (ru) |
| AU (1) | AU2019413682B2 (ru) |
| BR (1) | BR112021011633A2 (ru) |
| CA (1) | CA3125327A1 (ru) |
| CL (1) | CL2021001698A1 (ru) |
| EA (1) | EA202191075A1 (ru) |
| IL (1) | IL284302A (ru) |
| MX (1) | MX2021007815A (ru) |
| PH (1) | PH12021551133A1 (ru) |
| SG (1) | SG11202105229TA (ru) |
| WO (1) | WO2020140050A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4167999A4 (en) * | 2020-06-19 | 2024-03-06 | Endogena Therapeutics Inc | NOVEL COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENTED EPITHELIUM |
| US11541039B2 (en) | 2020-10-08 | 2023-01-03 | Endogena Therapeutics, Inc. | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216439A1 (en) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
| US6342516B1 (en) | 1998-07-31 | 2002-01-29 | Nippon Soda Co., Ltd. | Phenylazole compounds, process for producing the same and drugs for hyperlipemia |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| ES2453950T3 (es) | 2007-08-27 | 2014-04-09 | AbbVie Deutschland GmbH & Co. KG | 4-(4-Piridinil)-benzamidas y su uso como moduladores de la actividad de ROCK |
| JP2011506445A (ja) * | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| EP2234618A4 (en) | 2007-12-21 | 2011-04-27 | Scripps Research Inst | BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| US20130046003A1 (en) | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2014079850A1 (en) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
| DE102013110714A1 (de) | 2013-09-27 | 2015-04-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung |
| WO2015070170A1 (en) | 2013-11-08 | 2015-05-14 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| KR20220039853A (ko) | 2014-11-07 | 2022-03-29 | 더 존스 홉킨스 유니버시티 | N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 |
| CA2986692A1 (en) | 2015-05-29 | 2016-12-08 | Edge Therapeutics, Inc. | Compositions and methods for reducing visual loss |
-
2018
- 2018-12-28 US US16/235,429 patent/US10807973B2/en active Active
-
2019
- 2019-12-27 MX MX2021007815A patent/MX2021007815A/es unknown
- 2019-12-27 JP JP2021537222A patent/JP7492964B2/ja active Active
- 2019-12-27 SG SG11202105229TA patent/SG11202105229TA/en unknown
- 2019-12-27 WO PCT/US2019/068768 patent/WO2020140050A1/en unknown
- 2019-12-27 KR KR1020217023910A patent/KR20210110652A/ko unknown
- 2019-12-27 EP EP19842725.4A patent/EP3902798B1/en active Active
- 2019-12-27 CN CN201980085766.5A patent/CN113227086A/zh active Pending
- 2019-12-27 CA CA3125327A patent/CA3125327A1/en active Pending
- 2019-12-27 EA EA202191075A patent/EA202191075A1/ru unknown
- 2019-12-27 US US17/418,019 patent/US20220089583A1/en active Pending
- 2019-12-27 BR BR112021011633-8A patent/BR112021011633A2/pt unknown
- 2019-12-27 AU AU2019413682A patent/AU2019413682B2/en active Active
-
2021
- 2021-05-18 PH PH12021551133A patent/PH12021551133A1/en unknown
- 2021-06-22 IL IL284302A patent/IL284302A/en unknown
- 2021-06-24 CL CL2021001698A patent/CL2021001698A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202105229TA (en) | 2021-07-29 |
| JP7492964B2 (ja) | 2024-05-30 |
| US10807973B2 (en) | 2020-10-20 |
| EP3902798A1 (en) | 2021-11-03 |
| WO2020140050A1 (en) | 2020-07-02 |
| KR20210110652A (ko) | 2021-09-08 |
| EP3902798B1 (en) | 2023-12-20 |
| AU2019413682B2 (en) | 2023-11-23 |
| US20220089583A1 (en) | 2022-03-24 |
| AU2019413682A1 (en) | 2021-06-03 |
| EP3902798C0 (en) | 2023-12-20 |
| PH12021551133A1 (en) | 2022-02-21 |
| MX2021007815A (es) | 2021-10-01 |
| IL284302A (en) | 2021-08-31 |
| JP2022516087A (ja) | 2022-02-24 |
| CA3125327A1 (en) | 2020-07-02 |
| US20200207749A1 (en) | 2020-07-02 |
| CN113227086A (zh) | 2021-08-06 |
| CL2021001698A1 (es) | 2021-12-17 |
| BR112021011633A2 (pt) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015231234B2 (en) | Antifungal compound process | |
| JP2016518437A5 (ru) | ||
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| EA202191075A1 (ru) | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний | |
| RU2006112427A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| EA002763B1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2005506308A5 (ru) | ||
| ATE538784T1 (de) | Verfahren zur behandlung von substanzbedingten erkrankungen | |
| CA2962922A1 (en) | Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders | |
| JP2013522368A5 (ru) | ||
| MA27605A1 (fr) | Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel | |
| JP2004527492A5 (ru) | ||
| EA009193B1 (ru) | N-арилсульфонил-3-аминоалкоксииндолы | |
| PL90030B1 (ru) | ||
| RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
| RU2003128984A (ru) | Производные карбаматов для использования для лечения боли | |
| ATE378046T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen | |
| JP2005538974A5 (ru) | ||
| EA200700871A1 (ru) | Способы нейропротекции | |
| RU2004103079A (ru) | Новые иммуномодулирующие соединения | |
| JP2005517634A5 (ru) | ||
| RU2008123395A (ru) | Новые n-сульфамоил-n-бензопиранпиперидины, предназначенные для применения в медицине |